Pseudomyxoma Peritonei Clinical Trial
Official title:
Intratumoral Bromelain + N-acetylcysteine in Relapsed and Unresectable Pseudomyxoma Peritonei. Phase I Single-arm Trial
Verified date | June 2022 |
Source | Maimónides Biomedical Research Institute of Córdoba |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This trial pursues studying a compassionate treatment option for patients with inoperable pseudomyxoma peritonei through percutaneous administration of bromelain + N-acetylcysteine (NAC) in order to decrease tumoral volume. Secondary endpoints are the decrease of ascites, compressive symptoms and pain through the dilution of mucins, which would better intestinal blockage.
Status | Active, not recruiting |
Enrollment | 10 |
Est. completion date | May 16, 2023 |
Est. primary completion date | May 16, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Pseudomyxoma peritonei diagnosis through imaging tests and/or histological studies - Pseudomyxoma peritonei relapse in abdominal area in patients who comply inoperability criteria, which are: At least two HIPEC operations or major abdominal surgery (PSS > 3). Patients with acute morbidities (ASA score IV) - ECOG 0-2 - Age = 18 - Signs informed consent Exclusion Criteria: - Candidates to other potentially healing treatments - Allergy to bromelains (pineapple), N-Acetylcysteine or possible cross-reactive allergy (eggs, sulphate. latex, carrots, celery, wheat...) - Non-manageable coagulation alterations - No possibility of intraabdominal drainage catheter - Acute respiratory pathology (asthma, COPD), acute hepatic, cardiopathic or kidney pathology - Allergy to any substance that might cause crossed reactivity to bromelain - Unwillingness to participate in this clinical trial |
Country | Name | City | State |
---|---|---|---|
Spain | Hospital Universitario Reina Sofía | Córdoba |
Lead Sponsor | Collaborator |
---|---|
Maimónides Biomedical Research Institute of Córdoba |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Tumoral Mass Change | Tumoral mass change calculated through CT Scan or Magnetic Resonance categorized regarding the biggest diameter per abdominal region | Day 3, Day 7 (if it applies),1 month and 12 months after treatment is finished. | |
Secondary | Symptoms improvement | Symptoms progression evaluated through QLQ-C30 questionnaire (life quality questionnaire) | Basal visit, 1 month and 12 months after treatment. | |
Secondary | TTP (Time to tumor progression) | Period of time free of tumor progression. | Period of 12 months after treatment. | |
Secondary | Overall survival | Time until death from any cause | Period of 12 months after treatment. | |
Secondary | Tumoral DNA diminution in biological samples | Diminution of tumoral DNA amount found in mucin and blood samples | Basal visit, all treatment visits and 12 months after treatment is finished. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04024917 -
Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis
|
N/A | |
Completed |
NCT02374411 -
Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients
|
N/A | |
Recruiting |
NCT02073500 -
Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
|
||
Active, not recruiting |
NCT01427101 -
Results of CRS and Debulking in PMP Patients
|
N/A | |
Completed |
NCT04088786 -
Phase I Trial HIPEC With Nal-irinotecan
|
Phase 1 | |
Not yet recruiting |
NCT06084780 -
Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)
|
Phase 2 | |
Active, not recruiting |
NCT02834169 -
French National Registry of Rare Peritoneal Surface Malignancies
|
N/A | |
Completed |
NCT01764789 -
Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer
|
N/A | |
Completed |
NCT02040142 -
Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C
|
Phase 2 | |
Withdrawn |
NCT04125225 -
What Are the Experiences of Patients With Pseudomyxoma Peritonei?
|
||
Not yet recruiting |
NCT03976973 -
BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei
|
Phase 2 | |
Recruiting |
NCT01617382 -
Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed
|
||
Completed |
NCT01652794 -
Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer
|
Phase 1 | |
Completed |
NCT01126346 -
Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
|
N/A | |
Completed |
NCT05513183 -
Severe Neutropenia After HIPEC Using Mitomycin-C
|
||
Active, not recruiting |
NCT02834013 -
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
|
Phase 2 | |
Recruiting |
NCT03210298 -
International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)
|
||
Active, not recruiting |
NCT02387203 -
Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin
|
Phase 2 | |
Terminated |
NCT04665921 -
A Study of SGN-STNV in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05321329 -
Adjuvant CAPECITABINE in High Risk PSEUDOMYXOMA PERITONEI Patients
|
Phase 2 |